TWI369981B - Hmb compositions and uses thereof - Google Patents

Hmb compositions and uses thereof

Info

Publication number
TWI369981B
TWI369981B TW094109357A TW94109357A TWI369981B TW I369981 B TWI369981 B TW I369981B TW 094109357 A TW094109357 A TW 094109357A TW 94109357 A TW94109357 A TW 94109357A TW I369981 B TWI369981 B TW I369981B
Authority
TW
Taiwan
Prior art keywords
hmb
compositions
hmb compositions
Prior art date
Application number
TW094109357A
Other languages
English (en)
Chinese (zh)
Other versions
TW200539860A (en
Inventor
Jeffrey H Baxter
Anne C Voss
Pradip Mukerji
Michael J Tisdale
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of TW200539860A publication Critical patent/TW200539860A/zh
Application granted granted Critical
Publication of TWI369981B publication Critical patent/TWI369981B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
TW094109357A 2004-03-26 2005-03-25 Hmb compositions and uses thereof TWI369981B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/810,762 US20050215640A1 (en) 2004-03-26 2004-03-26 HMB compositions and uses thereof

Publications (2)

Publication Number Publication Date
TW200539860A TW200539860A (en) 2005-12-16
TWI369981B true TWI369981B (en) 2012-08-11

Family

ID=34990887

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094109357A TWI369981B (en) 2004-03-26 2005-03-25 Hmb compositions and uses thereof

Country Status (14)

Country Link
US (9) US20050215640A1 (https=)
EP (3) EP2301529B1 (https=)
JP (3) JP5145033B2 (https=)
KR (2) KR101253063B1 (https=)
CN (1) CN101212961A (https=)
AU (1) AU2005235133B2 (https=)
BR (1) BRPI0509017A (https=)
CA (2) CA2560042C (https=)
EC (1) ECSP066873A (https=)
ES (2) ES2586402T3 (https=)
IL (1) IL178039A0 (https=)
MX (1) MXPA06010922A (https=)
TW (1) TWI369981B (https=)
WO (1) WO2005102301A2 (https=)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
PL371081A1 (pl) * 2004-11-08 2006-05-15 Sgp & Sons Ab Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt
JP5227182B2 (ja) * 2005-12-19 2013-07-03 アボット・ラボラトリーズ １型および２型サイトカイン産生における不均衡を調節するためのベータ−ヒドロキシ−ベータ−メチルブチラートの使用
US9358242B2 (en) 2007-08-30 2016-06-07 Prelief Inc. Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9539224B2 (en) 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9770424B2 (en) 2008-12-09 2017-09-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
WO2010068696A1 (en) 2008-12-09 2010-06-17 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
EP2400839B1 (en) 2009-02-24 2016-09-07 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PT3278665T (pt) 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
CN106074486A (zh) 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
CN101704736A (zh) * 2009-10-30 2010-05-12 黄再新 β-羟基-β-甲基丁酸生产过程中氯气逸出时的应急处理方法
US8490829B2 (en) 2009-11-24 2013-07-23 Pepsico, Inc. Personalized beverage dispensing device
US9754437B2 (en) * 2009-11-24 2017-09-05 Pepsico, Inc. Automated beverage formulation
US8335592B2 (en) 2009-11-24 2012-12-18 Pepsico, Inc. Beverage dispensing device
EP2512236B1 (en) * 2009-12-18 2016-10-19 Metabolic Technologies, Inc. Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb)
ES2481865T3 (es) * 2010-01-29 2014-07-31 Abbott Laboratories Emulsiones nutricionales que comprenden HMB de calcio
BR112012018174A2 (pt) * 2010-01-29 2019-08-27 Abbott Lab líquidos nutricionais embalados assepticamente compreendendo hmb.
CA2785522C (en) * 2010-01-29 2015-09-29 Abbott Laboratories Nutritional emulsions comprising calcium hmb and soluble protein
PH12012501350A1 (en) * 2010-01-29 2016-07-08 Abbott Lab Nutritional powders comprising spray dried hmb
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
SG182807A1 (en) * 2010-01-29 2012-09-27 Abbott Lab Plastic packaged nutritonal liquids comprising hmb
EP3202406A1 (en) 2010-04-28 2017-08-09 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
EP2444083A1 (en) 2010-10-21 2012-04-25 Nestec S.A. Cysteine and food intake
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
BR112013016187A2 (pt) * 2010-12-22 2018-07-10 Abbott Lab Produtos nutricionais compreendendo beta- hidróxi-beta metilbutirato de cálcio e ácido linoléico conjungado.
CN103269695A (zh) * 2010-12-27 2013-08-28 雅培制药有限公司 使用β-羟基-β-甲基丁酸盐促进废用一段时期之后肌肉恢复的方法
PH12013501597A1 (en) * 2011-02-07 2013-09-30 Abbott Lab Nutritional products comprising beta-hydroxy-beta-methylbutyrate
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
BR112013020643A2 (pt) 2011-02-17 2016-08-02 Abbott Lab métodos para melhorar o desenvolvimento cerebral e a função cognitiva usando beta-hidróxi-beta-metilbutirato
AU2012237345A1 (en) * 2011-03-31 2013-09-19 Nestec S.A. Nutritional compositions for increasing arginine levels and methods of using same
US8183227B1 (en) 2011-07-07 2012-05-22 Chemo S. A. France Compositions, kits and methods for nutrition supplementation
JP2014525410A (ja) * 2011-08-15 2014-09-29 アボット・ラボラトリーズ Ｈｍｂ及びその塩を製造する方法
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
ES2421187B1 (es) * 2012-02-23 2014-11-26 Abbott Laboratories Metodo para mejorar el desarrollo cerebral y la funcion cognitiva usando beta-hidroxi-beta-metilbutirato
US20150119339A1 (en) * 2012-06-11 2015-04-30 Abbott Laboratories Use of hmb to improve health outcomes for hospitalized patients
EP4338805B1 (en) 2012-06-29 2025-06-04 Amarin Pharmaceuticals Ireland Limited Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy
US20140037813A1 (en) * 2012-08-02 2014-02-06 Mead Johnson Nutrition Company Nutritional creamer composition
US10092590B2 (en) * 2012-09-10 2018-10-09 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
US20150238447A1 (en) * 2012-09-17 2015-08-27 Abbott Laboratories Beta-hydroxy-beta-methylbutryic acid-containing compositions and uses thereof
MX2015003660A (es) 2012-09-21 2015-06-05 Abbott Lab Composiciones nutricionales que incluyen beta-hidroxi-beta-metilbu tirato de calcio, proteina y bajos niveles de electrolitos.
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
WO2014113404A1 (en) * 2013-01-15 2014-07-24 Nusirt Sciences, Inc. Treating pulmonary conditions
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9820504B2 (en) 2013-03-08 2017-11-21 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
WO2014138304A1 (en) 2013-03-08 2014-09-12 Axiom Foods, Inc., Rice protein supplements
JP2016513701A (ja) 2013-03-14 2016-05-16 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 長期身体不活動に関連するインスリン抵抗性の治療
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150057350A1 (en) * 2013-08-23 2015-02-26 Abbott Laboratories Fibrosis biomarkers and methods of using same
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
JP6349575B2 (ja) * 2013-12-03 2018-07-04 小林香料株式会社 Ｈｍｂを含有する酸性飲料
EP3082778B1 (en) 2013-12-18 2019-04-03 Capsugel Belgium NV Stable liquid filled hard capsule comprising beta-hydroxy-beta-methylbutyric acid
WO2015094767A1 (en) * 2013-12-18 2015-06-25 Abbott Laboratories Methods for maintaining or increasing bodyweight using decaffeinated green tea extract
WO2015105981A2 (en) * 2014-01-09 2015-07-16 Abbott Laboratories Conditional essentiality of hmb
JP6480964B2 (ja) * 2014-03-14 2019-03-13 メタボリック・テクノロジーズ，インコーポレーテッド 遊離酸形のβ−ヒドロキシ−β−メチル酪酸（ＨＭＢ）を含有する液体及び食品ならびにその製造法
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US20160184248A1 (en) * 2014-12-15 2016-06-30 University Of Central Florida Research Foundation Inc. Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response
WO2016196637A1 (en) * 2015-06-01 2016-12-08 Metabolic Technologies, Inc. Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for decreasing fat mass
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
PT3349745T (pt) 2015-09-16 2024-03-18 Metabolic Tech Inc Composições e métodos de utilização de beta-hidroxi-beta metilbutirato (hmb) para melhorar a recuperação de traumatismos de tecidos moles
CN108697675A (zh) * 2016-01-13 2018-10-23 代谢科技有限公司 用于关节稳定性的β-羟基-β-甲基丁酸(HMB)的组合物和使用方法
WO2017127675A1 (en) * 2016-01-21 2017-07-27 Metabolic Technololgies, Inc. COMPOSITIONS AND METHODS OF USE OF β-HYDROXY-β-METHYLBUTYRATE (HMB) FOR MODULATING AUTOPHAGY AND LIPOPHAGY
US11406609B2 (en) 2016-01-21 2022-08-09 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for modulating autophagy and lipophagy
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2017205673A1 (en) 2016-05-25 2017-11-30 TSI Group Ltd. Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JP7136807B2 (ja) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
EP3634155A4 (en) 2017-05-12 2021-02-17 Axiom Foods Inc. RICE PRODUCTS AND SYSTEMS AND PROCESSES FOR THEIR PRODUCTION
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
MX2020001765A (es) 2017-08-14 2020-07-29 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica.
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
CN108558707A (zh) * 2018-04-13 2018-09-21 太仓运通新材料科技有限公司 一种三肌酸hmb盐的制备方法
JP7250810B2 (ja) * 2018-04-25 2023-04-03 オンコクロス カンパニー，リミテッド 筋肉疾患の予防及び治療用組成物
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
IL261670B (en) * 2018-09-06 2019-06-30 Tudu Holdings Ltd Magnesium-containing formulation and uses thereof
KR20210110890A (ko) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
US10888576B2 (en) 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
JP7286964B2 (ja) * 2018-12-28 2023-06-06 日油株式会社 β－ヒドロキシ－β－メチル酪酸、タンパク質、及び液状油脂を含有する液状栄養組成物
CN111714616A (zh) * 2019-07-17 2020-09-29 江苏西宏生物医药有限公司 一种用于抗肿瘤的组合物
JP7594356B2 (ja) * 2019-10-30 2024-12-04 小林製薬株式会社 経口組成物
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
EP4117646A1 (en) * 2020-03-12 2023-01-18 Abbott Laboratories Methods of treating diarrhea or inflammatory conditions of the gut
AU2021292308A1 (en) * 2020-06-17 2023-02-09 Metabolic Technologies, LLC Compositions and methods of use of betaeta-hydroxy-betaeta-methylbutyrate (hmb) for improving muscle mass, strength and muscular function without exercise
US20230398104A1 (en) * 2020-10-30 2023-12-14 Societe Des Produits Nestle S.A. Compositions containing nicotinamide and vitamin b6 and methods of using such compositions for rehabilitation
AU2021370938A1 (en) * 2020-10-30 2023-04-13 Société des Produits Nestlé S.A. Compositions containing Nicotinamide and Vitamin B6 and methods of using such compositions for promoting muscle growth
AU2021372803A1 (en) * 2020-10-30 2023-04-06 Société des Produits Nestlé S.A. Compositions containing nicotinamide and vitamin B6 and methods of using such compositions for treating cachexia or precachexia
BR112023004232A2 (pt) * 2020-10-30 2023-05-09 Nestle Sa Composições contendo nicotinamida e vitamina b6 e métodos de uso de tais composições para tratar sarcopenia e debilidade
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
EP4395756A1 (en) * 2021-08-31 2024-07-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of branched chain fatty acids (bcfas) for the treatment of intestinal inflammation
DE202023107635U1 (de) * 2023-12-22 2024-02-08 RenaCare NEPHROMED GmbH Zusammensetzung zur Eiweißsubstitution

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US597650A (en) 1898-01-18 morris
US3408210A (en) 1965-06-14 1968-10-29 Wilbert A. Heyman Dehydration of foods
US3542560A (en) 1967-12-06 1970-11-24 American Home Prod Infant formula with fat composition like human milk
GB1446965A (en) 1974-02-14 1976-08-18 Agricultural Vegetable Prod Preparation of food products
US4104290A (en) 1975-02-07 1978-08-01 H.L.S. Ltd., Industrial Engineering Company Process for separating oils and fats into liquid and solid fractions
US4311645A (en) 1980-03-24 1982-01-19 Hoffmann-La Roche Inc. Synthesis of SRS-active compounds
US4871768A (en) 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US4866040A (en) * 1986-01-06 1989-09-12 Alfred Stracher Aminocarnitine directed pharmaceutical agents
US4742081A (en) * 1986-01-06 1988-05-03 Alfred Stracher Carnitine coupled pharmaceutical agents
DE3620433A1 (de) 1986-06-18 1987-12-23 Boehringer Ingelheim Kg Verwendung von 2-(n-2,6-dichlorphenyl-n-allyl-amino)-imidazolin-(2) als cytoprotektives mittel
ES2052066T3 (es) 1988-10-31 1994-07-01 Sandoz Nutrition Ltd Mejoras en o relacionadas con compuestos organicos.
US5000975A (en) 1988-12-29 1991-03-19 American Home Products Corporation Randomized palm oil fat composition for infant formulas
CA2010511A1 (en) 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US5457130A (en) * 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
GB8906369D0 (en) * 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
US5157022A (en) 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5167957A (en) 1990-09-06 1992-12-01 Virginia Tech Intellectual Properties, Inc. Compositions and methods for the treatment of dietary deficiencies
US5601860A (en) 1990-11-30 1997-02-11 American Home Products Corporation Corandomized fat compositions for infant formulas
KR100219771B1 (ko) 1991-03-18 1999-10-01 이치로 키타사토 돼지용 사료 및 이를 사용하는 돼지 사육법
US5085883A (en) 1991-06-27 1992-02-04 Abbott Laboratories Blend of dietary fiber for nutritional products
US5171442A (en) 1991-10-18 1992-12-15 Nakshbendi Ghassan F Water purification apparatus
US5223285A (en) 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
ES2142353T3 (es) * 1992-09-16 2000-04-16 Univ Iowa State Res Found Inc Procedimiento para reducir los niveles de colesterol total y de colesterol asociado a lipoproteinas de baja densidad en sangre.
US5447732A (en) 1992-11-25 1995-09-05 Ajinomoto Co., Inc. High-absorption mineral-containing composition and foods
US5348979A (en) 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
JP2761294B2 (ja) 1993-05-13 1998-06-04 ロデルス−クロクラーン エステル交換トリグリセリドブレンド由来のヒト母乳脂肪代用品
US6136858A (en) 1994-01-10 2000-10-24 Abbott Laboratories Infant formula and methods of improving infant stool patterns
US5952314A (en) 1994-04-01 1999-09-14 Demichele; Stephen Joseph Nutritional product for a person having ulcerative colitis
US5444054A (en) 1994-04-01 1995-08-22 Abbott Labatories Method of treating ulcerative colitis
US5780451A (en) 1994-04-01 1998-07-14 Abbott Laboratories Nutritional product for a person having ulcerative colitis
US5576287A (en) 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
US5726146A (en) * 1994-12-06 1998-03-10 Natural Supplement Association, Incorporated Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass
KR0140248B1 (ko) 1995-03-23 1998-06-15 한상기 신규한 카제인 포스포펩티드, 그것을 포함하는 카제인 및 그 제조방법
DE19528461A1 (de) * 1995-08-03 1997-02-06 Braun Melsungen Ag Präparat zur Ernährung
US5641531A (en) 1995-09-28 1997-06-24 Abbott Laboratories Nutritional liquid supplement beverage and method of making same
WO1997021360A1 (en) 1995-12-15 1997-06-19 The Procter & Gamble Company Beverages having stable flavor/cloud emulsions in the presence of polyphosphate-containing preservative systems and low levels of xanthan gum
WO1997037546A1 (en) 1996-04-11 1997-10-16 Loders Croklaan B.V. Free flowing fat compositions
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US5756469A (en) 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US7504376B2 (en) 1996-08-12 2009-03-17 Natural Alternatives International Methods and compositions for increasing the anaerobic working capacity in tissues
US6080788A (en) 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
DE29707308U1 (de) 1997-04-23 1997-06-26 Kunz, Armin, 66450 Bexbach Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
US6103764A (en) * 1997-11-07 2000-08-15 Iowa State University Research Foundation, Inc. Method for increasing the aerobic capacity of muscle
US6013665A (en) 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
US6194379B1 (en) 1998-05-01 2001-02-27 Abbott Laboratories Elemental enteral formula
US6475539B1 (en) 1998-05-07 2002-11-05 Abbott Laboratories Nutritionally complete low pH enteral formula
JP4175698B2 (ja) 1998-06-19 2008-11-05 サントリー株式会社 新規なトリグリセリド及びそれを含む組成物
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
CA2338638C (en) 1998-07-30 2009-03-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
US5976550A (en) * 1998-11-20 1999-11-02 Engel; Peter H. Dietary food supplement
US20010008641A1 (en) * 1998-11-25 2001-07-19 R. Douglas Krotzer Nutritionally active composition for bodybuilding
JP3973786B2 (ja) 1998-12-28 2007-09-12 松下電器産業株式会社 スパッタリング方法及び装置
US6294206B1 (en) 1999-04-09 2001-09-25 Abbott Laboratories Powdered human milk fortifier
US6291525B1 (en) 1999-09-08 2001-09-18 Iowa State University Research Foundation, Inc. Method for improving a human's perception of his emotional state
EP1221865B1 (en) 1999-10-18 2007-01-03 Muscletech Research and Development Inc. Food supplement for increasing lean mass and strength
GB9929919D0 (en) 1999-12-17 2000-02-09 Hannah Research Inst The Calcium phosphate nanoclusters and their applications
US6521591B1 (en) 2000-02-10 2003-02-18 N.V. Nutricia Pharmaceutical composition for muscular anabolism
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
CA2404799C (en) 2000-04-06 2007-08-07 Conlinco, Inc. Conjugated linoleic acid compositions
JP4625156B2 (ja) * 2000-04-10 2011-02-02 イーエヌ大塚製薬株式会社 癌化学療法に伴う副作用軽減剤
US6420342B1 (en) 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof
US20050106219A1 (en) 2000-05-30 2005-05-19 Karlheinz Bortlik Primary composition comprising a lipophilic bioactive compound
US6592878B2 (en) 2000-08-03 2003-07-15 North Carolina State University Enhancement of development of oviparous species by in ovo feeding
US20030176514A1 (en) 2000-08-29 2003-09-18 Martin Fuhrmann Method for preparing a mixture that can be granulated and carnitine-magnesium hydroxycitrate
US20030203070A1 (en) 2000-09-26 2003-10-30 The Procter & Gamble Company Compositions containing sorbitan monoesters
EP1198991B1 (en) 2000-10-20 2012-12-19 Nutriz N.V: Non-dairy products derived from rice
US20030165604A1 (en) 2001-02-15 2003-09-04 Kazufumi Tsubaki Products containing $g(b)-glucan
JP3735070B2 (ja) 2001-03-26 2006-01-11 花王株式会社 容器詰乳化飲料
US6620427B2 (en) 2001-04-24 2003-09-16 Abbott Laboratories Method for improving bone mineralization
US20030021877A1 (en) 2001-06-13 2003-01-30 Cain Frederick William Micronised fat particles
DE10145818C1 (de) 2001-09-17 2002-10-10 Alfill Engineering Gmbh & Co K Sterilisiervorrichtung mit H202-Verdampfer
JP2003137790A (ja) * 2001-11-01 2003-05-14 Mie Kariyou Kk β−２，１（β２→β１）結合連鎖フラクトースオリゴマーを含有するフラクトオリゴ糖を有効成分とする医薬
GB2381451A (en) 2001-11-01 2003-05-07 New Technology Res Ltd Pharmaco-dietary preparation having nutrition-supplementing and nutrition-enhancing effect
US7419596B2 (en) 2001-12-12 2008-09-02 Martek Biosciences Corporation Extraction and winterization of lipids from oilseed and microbial sources
DE10163676A1 (de) 2001-12-21 2003-07-10 Phenion Gmbh & Co Kg Verwendung von Hyperforin oder Extrakten aus Johanniskraut gegen anaphylaktische Schockzustände oder Osteoporose
US7168581B2 (en) 2001-12-21 2007-01-30 Rexam Medical Packaging Inc. Closure for a retort processed container having a peelable seal
US20030165579A1 (en) 2002-02-27 2003-09-04 Chih-Hui Lin Euphorbia antiquorum extract, a pharmaceutical composition containing the same and methods for treatment of cancers
DE60328675D1 (de) 2002-04-23 2009-09-17 Aventis Pharma Inc 3-(substitutierte amino)-1h-indole-2-carbonsäureester und 3-(substitutierte amino)-benzoäbüthiophen-2-carbonsäureester verbindungen als inhibitoren der interleukin-4 genexpression
SE0201581D0 (sv) 2002-05-29 2002-05-29 Scandinavian Biotechnology Res New improved acyltransferase
US20040013787A1 (en) 2002-06-28 2004-01-22 Theuer Richard C. Fat compositions for infant formula and methods therefor
US20040048925A1 (en) 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
WO2004035624A2 (en) 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
US7445807B2 (en) * 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
US7332178B2 (en) 2003-04-25 2008-02-19 Abbott Laboratories Stable nutritional powder containing ascorbyl palmitate
FR2856596B1 (fr) 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
JP2008500271A (ja) 2003-10-14 2008-01-10 ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン 免疫介在性疾患の治療および／または予防におけるアデニル酸シクラーゼ
IL158555A0 (en) 2003-10-22 2004-05-12 Enzymotec Ltd Human breast milk lipid mimetic as dietary supplement
DE602004016385D1 (de) 2003-12-24 2008-10-16 Nutricia Nv Zusammensetzungen mit pantothensäure oder derivaten davon und ihre verwendung zur stimulierung des appetits
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20050249650A1 (en) 2004-05-07 2005-11-10 Fmc Technologies, Inc. Immersion retort
MX2007002912A (es) 2004-09-09 2007-05-16 Nestec Sa Productos nutricionales teniendo calidad mejorada y metodos y sistemas considerando los mismos.
US8557551B2 (en) 2004-09-10 2013-10-15 Dsm Ip Assets B.V. Compositions and methods for making and modifying oils
PL371081A1 (pl) 2004-11-08 2006-05-15 Sgp & Sons Ab Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt
US8067052B2 (en) 2005-02-25 2011-11-29 Siddharth Shastri Nutritional composition and a container for the convenient transport and storage of the nutritional composition
CA2537452C (en) 2005-03-09 2013-12-24 Abbott Laboratories Concentrated human milk fortifier liquid
RU2413430C2 (ru) 2005-04-27 2011-03-10 Энзимотек Лтд. Композиция жировой основы (варианты) и способ ее получения (варианты), композиция заменителя жира женского молока и способ ее получения (варианты), смесь для детского питания
CA2606300A1 (en) 2005-06-06 2006-12-14 Bristol-Myers Squibb Company Low-phytate infant formulas
JP2009506012A (ja) 2005-08-26 2009-02-12 ネステク ソシエテ アノニム 肥満患者の栄養素
MY147363A (en) 2005-09-20 2012-11-30 Nestec Sa Water dispersible composition and method for preparing same
US20090182050A1 (en) 2005-10-07 2009-07-16 Ocean Nutrition Canada, Ltd. Salts of Fatty Acids and Methods of Making and Using thereof
WO2007056176A2 (en) 2005-11-03 2007-05-18 Southwest Immunology, Inc. Compositions for preventing and reducing delayed onset muscle soreness
JP5227182B2 (ja) 2005-12-19 2013-07-03 アボット・ラボラトリーズ １型および２型サイトカイン産生における不均衡を調節するためのベータ−ヒドロキシ−ベータ−メチルブチラートの使用
PL1981358T3 (pl) 2006-01-31 2011-04-29 Nestec Sa Kompozycja żywieniowa dla noworodków z niską wagą urodzeniową
US20080119552A1 (en) 2006-11-17 2008-05-22 Novus International Inc. Matrix-embedded compositions having organic acids and fatty acids
US20080194407A1 (en) 2007-02-14 2008-08-14 Ashmead H Dewayne High nitrogen containing chelate compositions suitable for plant delivery
US20090110674A1 (en) 2007-10-24 2009-04-30 Loizou Nicos C Health supplement
US8029830B2 (en) 2008-04-18 2011-10-04 Nuvocare Health Services Inc. Composition and method for promoting internal health and external appearance
BRPI0912571A2 (pt) 2008-05-21 2015-07-28 Stokely Van Camp Inc Bebida de recuperação à base de leite
WO2010068696A1 (en) 2008-12-09 2010-06-17 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
JP2009155336A (ja) 2009-03-31 2009-07-16 Tsujido Chemical Corp 治療剤
US20090312419A1 (en) 2009-08-12 2009-12-17 Kneller Bruce W CREATINE -ßALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE
PL217815B1 (pl) 2009-12-14 2014-08-29 Olimp Lab Spółka Z Ograniczoną Odpowiedzialnością Napój izotoniczny z chelatami
CN101785566A (zh) 2010-01-22 2010-07-28 北京康比特体育科技股份有限公司 一种含有hmb的运动饮料
ES2481865T3 (es) 2010-01-29 2014-07-31 Abbott Laboratories Emulsiones nutricionales que comprenden HMB de calcio
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
US10869843B2 (en) 2010-11-23 2020-12-22 Chemi Nutra Method for increasing muscle mass and strength
CN103269695A (zh) 2010-12-27 2013-08-28 雅培制药有限公司 使用β-羟基-β-甲基丁酸盐促进废用一段时期之后肌肉恢复的方法
WO2012097061A1 (en) 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for improving skeletal muscle protein metabolism
WO2013056048A2 (en) 2011-10-13 2013-04-18 Abbott Laboratories Nutritional products comprising beta-alanine
WO2013170189A1 (en) 2012-05-11 2013-11-14 Abbott Laboratories Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow
US20150119339A1 (en) 2012-06-11 2015-04-30 Abbott Laboratories Use of hmb to improve health outcomes for hospitalized patients

Also Published As

Publication number Publication date
JP5145033B2 (ja) 2013-02-13
AU2005235133A1 (en) 2005-11-03
EP2444082A2 (en) 2012-04-25
US20120177752A1 (en) 2012-07-12
JP5732437B2 (ja) 2015-06-10
WO2005102301A3 (en) 2006-10-26
US20120189715A1 (en) 2012-07-26
EP1727534A2 (en) 2006-12-06
JP2007530542A (ja) 2007-11-01
EP2301529B1 (en) 2016-07-20
CN101212961A (zh) 2008-07-02
ES2586402T3 (es) 2016-10-14
JP2015147773A (ja) 2015-08-20
US8785495B2 (en) 2014-07-22
US20120189717A1 (en) 2012-07-26
HK1155972A1 (en) 2012-06-01
CA2807787A1 (en) 2005-11-03
ECSP066873A (es) 2006-11-24
US8785496B2 (en) 2014-07-22
KR20060134181A (ko) 2006-12-27
US8609725B2 (en) 2013-12-17
KR20130010912A (ko) 2013-01-29
US20050215640A1 (en) 2005-09-29
AU2005235133B2 (en) 2010-06-17
CA2807787C (en) 2014-08-12
EP2444082B1 (en) 2018-09-12
JP2012229227A (ja) 2012-11-22
US20130011498A1 (en) 2013-01-10
CA2560042C (en) 2014-02-11
EP2444082A3 (en) 2012-08-01
US8778993B2 (en) 2014-07-15
EP2301529A1 (en) 2011-03-30
US20070093553A1 (en) 2007-04-26
IL178039A0 (en) 2007-07-04
CA2560042A1 (en) 2005-11-03
ES2699161T3 (es) 2019-02-07
TW200539860A (en) 2005-12-16
MXPA06010922A (es) 2006-12-15
WO2005102301A2 (en) 2005-11-03
US20120196829A1 (en) 2012-08-02
US8778994B2 (en) 2014-07-15
US8217077B2 (en) 2012-07-10
BRPI0509017A (pt) 2007-08-07
US20120189716A1 (en) 2012-07-26
US20120189714A1 (en) 2012-07-26
KR101253063B1 (ko) 2013-04-11

Similar Documents

Publication Publication Date Title
TWI369981B (en) Hmb compositions and uses thereof
GB0422525D0 (en) Dermatological compositions and methods
IL183581A0 (en) Viscosupplementation devices and compositions
ZA200704295B (en) Arthrospira-based compositions and uses thereof
EP1802588A4 (en) SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF
PL2218342T3 (pl) Nowe kompozycje nutraceutyczne i ich zastosowanie
IL180762A (en) Oligomer-insulin conjugates, formulations containing them and their use
GB0411940D0 (en) Methods and compositions
IL191072A0 (en) Therapeutic compositions and methods
IL183986A0 (en) Pharmaceutical compounds and compositions
IL182126A (en) Preparations containing and used in the history of 5-phenoxyalkoxypsoralen
EP1890677A4 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE
ZA200706128B (en) Pesticide compositions and methods
IL179497A0 (en) Carboranylporphyrins and uses thereof
EP1807071A4 (en) ANTIPYRETIC METHODS AND COMPOSITIONS
EP1948159A4 (en) PHARMACEUTICAL COMPOSITIONS OF GALLIUM AND METHODS
IL186337A0 (en) Stannsoporfin compositions and administration
IL180365A0 (en) Carboranylporphyrins and uses thereof
GB0424051D0 (en) Compounds and compositions
GB0325942D0 (en) Compositions and uses thereof
GB0207224D0 (en) Tenascin-W compositions and uses thereof
GB0501348D0 (en) Compositions and methods
EP1865777A4 (en) STANNSOPORFIN COMPOSITIONS AND ADMINISTRATION
ZA200610727B (en) Compositions comprising strontium and vitamin D and uses thereof
GB0309509D0 (en) Pharmaceutical compositions and their uses

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees